Actively Recruiting
Evaluating Xiidra Eye Drops for Treating Eye Discomfort in Glaucoma Patients Using Multiple Eye Medications
Led by University of California, Los Angeles · Updated on 2026-03-13
75
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate how glaucoma patients respond to treatment with Xiidra Lifitegrast ophthalmic solution 5%, an FDA-approved eye drop used for ocular surface discomfort. The study focuses on discomfort caused partly by the use of topical glaucoma antihypertensive medications. The purpose is to better understand the effects of Xiidra when prescribed as part of standard care for these patients. Participants will use Xiidra eye drops in both eyes for a period of 12 weeks. The treatment is administered topically and is part of the patients usual glaucoma care. The study observes changes in symptoms related to ocular surface discomfort over this 12-week treatment period. During the study, participants will be assessed at baseline and at weeks 2, 6, and 12. Researchers will measure changes in corneal fluorescein staining scores, eye dryness scores, and ocular surface disease index OSDI questionnaire scores to evaluate the treatments impact. These assessments help monitor how symptoms evolve with treatment, and participants safety and response will be observed throughout the study duration.
CONDITIONS
Brief Title
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
Research Team
B
Benjamin B Bert, MD
M
Mayra Raygoza
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here